Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Adjusting the dose of tamoxifen in patients with early breast cancer and CYP2D6 poor metabolizer phenotype.

Breast (Edinburgh, Scotland) - 1 Aug 2014

Martinez de Dueñas Eduardo, Ochoa Aranda Enrique, Blancas Lopez-Barajas Isabel, Ferrer Magdalena Teresa, Bandrés Moya Fernando, Chicharro García Luis Miguel, Gómez Capilla José A, Zafra Ceres Mercedes, de Haro Tomás, Romero Llorens Regina, Ferrer Albiach Carlos, Ferriols Lisart Rafael, Chover Lara Dolores, López Rodríguez Angela, Munárriz Ferrandis Javier, Olmos Antón Santiago

Abstract excerpt

BACKGROUND: CYP2D6 is a key enzyme in tamoxifen metabolism, transforming it into its main active metabolite, endoxifen. Poor CYP2D6 metabolizers (PM) have lower endoxifen plasma concentrations and possibly benefit less from treatment with tamoxifen. We evaluated tamoxifen dose adjustment in CYP2D6 PM patients in order to obtain plasma concentrations of endoxifen comparable to patients with extensive CYP2D6...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Antineoplastic Agents, Hormonal

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Breast Neoplasms

Share to Cytochrome P-450 CYP2D6

Share to Genotype

Share to Phenotype

Share to Tamoxifen

Source

Identifiers

PMID: 24685597
DOI: 10.1016/j.breast.2014.02.008

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Adjusting the dose of tamoxifen in patients with early breast cancer and CYP2D6 poor metabolizer phenotype.PMID 24685597Read ↗

Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study.Semantic proximity Read ↗

CYP2D6 genotype- and endoxifen-guided tamoxifen dose escalation increases endoxifen serum concentrations without increasing side effects.Semantic proximity Read ↗

Observed tamoxifen drug interactions are dependent on both CYP2D6 phenotype and inhibitor potency.Semantic proximity Read ↗

Tamoxifen Dose Escalation in Patients With Diminished CYP2D6 Activity Normalizes Endoxifen Concentrations Without Increasing Toxicity.Semantic proximity Read ↗

The Effect of Tamoxifen Dose Increment in Patients With Impaired CYP2D6 Activity.Semantic proximity Read ↗

Use of <i>CYP2D6</i> Genotyping in Practice: Tamoxifen Dose AdjustmentSemantic proximity Read ↗

Clinical CYP2D6 Genotyping to Personalize Adjuvant Tamoxifen Treatment in ER-Positive Breast Cancer Patients: Current Status of a ControversySemantic proximity Read ↗

Personalized medicine in breast cancer: tamoxifen, endoxifen, and CYP2D6 in clinical practice.Semantic proximity Read ↗

CYP2D6 and Endoxifen in Tamoxifen Therapy: A Tribute to David A. Flockhart.Semantic proximity Read ↗

Early increase in tamoxifen dose in CYP2D6 poor metaboliser breast cancer patients and survival: A propensity score matching analysis.Semantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy.Semantic proximity Read ↗

Clinical pharmacokinetics and pharmacogenetics of tamoxifen and endoxifenSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.